InCytu Inc, Lincoln, RI 02865, USA.
Expert Opin Biol Ther. 2009 Dec;9(12):1453-61. doi: 10.1517/14712590903307396.
This perspective is part of an ongoing series of articles that describe the drugs that were dropped from clinical development during the previous year. This paper focuses on those drugs that were discontinued in 2008. The drugs represent a diverse collection of compounds targeted at diseases including cancer, diabetes, infections, arthritis, HIV, restenosis, allergies, anaemia, osteoporosis, wound healing, and growth deficiency. No consistent theme is apparent that accounts for the diversity of discontinued drugs. Still, this diversity, coupled with the numbers of novel drugs that were approved in 2008 suggests a healthy ongoing drug development process.
本观点是正在进行的一系列文章的一部分，这些文章描述了前一年临床开发中被淘汰的药物。本文重点介绍了 2008 年被淘汰的药物。这些药物代表了针对各种疾病的多种化合物，包括癌症、糖尿病、感染、关节炎、艾滋病、再狭窄、过敏、贫血、骨质疏松、伤口愈合和生长缺陷。没有一个明显的主题可以解释被淘汰药物的多样性。尽管如此，这种多样性，再加上 2008 年批准的新药数量，表明了一个健康的药物开发过程正在进行中。
